Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Efficacy and Safety of Filgotinib Administered for 16 Weeks to Subjects With Moderately to Severely Active Psoriatic Arthritis

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 05 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

07 May 2026 According to Galapagos NV media release, Galapagos NV is now called Lakefront Biotherapeutics.
09 Nov 2021 Results of whole-blood RNA-Seq data analysis evaluatingthe impact of Filgotinib on gene expression and biological pathways, presented at the ACR Convergence 2021
05 Jun 2021 Results of a post-hoc analysis from EQUATOR and EQUATOR 2 (up to OLE week 100) assessing effect of Filgotinib on individual PASDAS socre components and association between PASDAS disease activity levels presented at the 22nd Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com